CLINICAL NEWS

Lilly announces withdrawal of septic shock treatment following recent clinical trial results

Eli Lilly and Company has announced a worldwide withdrawal of its drotrecogin alfa (activated) (Xigris) in all markets following results of the PROWESS-SHOCK study, regarding patients with septic shock. » More

ACIP votes for expanded use of HPV vaccine in boys, young men

The CDC's ACIP voted to recommend that boys aged 11 to 12 years be vaccinated routinely with human papillomavirus (HPV) quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant (Gardasil, Merck) to help prevent cancers and other diseases caused by HPV. » More

NHLBI halts triple therapy arm of IPF study due to safety concerns

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, announced it has stopped 1 arm of a 3-arm, multicenter, clinical trial studying treatments for idiopathic pulmonary fibrosis due to safety concerns. » More

ADVERTISEMENT

Resource Center: Oral Anticoagulation in Atrial Fibrillation

Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies, click here.

Survey

With specialty pharmacy representing the most rapidly growing component of most pharmacy budgets today, in what specific area do you believe specialty pharmacies most need to expand their service offerings to better support the needs of payers?

a) Improved adherence programming
b) Enhanced safety and outcomes monitoring/reporting
c) More proactive pipeline monitoring and forecasting
d) Advanced healthcare IT to better communicate and integrate care across the healthcare continuum
e) More comprehensive patient/provider education
f) Other

Respond here and see what your colleagues think too.

Want to see the results of our last survey regarding health systems’ oncology medication approval process?
Click here.

Editor's Pick

Osteoporosis

A review of current recommendations and emerging treatment options for osteoporosis.
» Click here.

FDA’s AERS provides surprising look at statin class side effects, study shows

Findings culled from a new method for aggregating and making sense of data in the FDA’s Adverse Event Reporting System present a surprising glimpse at the postmarketing adverse event data for statins. » More

Letrozole more effective than tamoxifen at reducing breast cancer recurrence, mortality in postmenopausal women

When compared with tamoxifen montherapy, letrozole (Femara, Novartis) monotherapy was more effective at preventing breast cancer recurrence and improving survival among postmenopausal women with endocrine-responsive early breast cancer, according to a long-term follow-up published online October 21 in Lancet Oncology. » More

FDA ACTIONS

FDA approves first generic olanzapine to treat schizophrenia, bipolar disorder

FDA has approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder. » More

FDA approves bupivacaine injection for post-surgical pain management

FDA has approved bupivacaine liposome injectable suspension (Exparel, Pacira Pharmaceuticals) 1.3% for administration into the surgical site to produce post-surgical analgesia. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

Resources

Digital Edition